Dr. Maher Albitar is the founder and Chief Executive Officer and Chief Medical Officer of Genomic Testing Cooperative, LCA. Dr. Albitar has extensive experience in anatomic/clinical pathology, hematopathology and molecular pathology. Until 2018, Dr. Albitar was the Senior Vice President, Chief Medical Officer and Director of Research and Development at NeoGenomics Laboratories. Prior to NeoGenomics, Dr. Albitar served as the Medical Director for Hematopathology and Oncology, Nichols Institute, Quest Diagnostics, and Chief R&D for Hematopathology and Oncology for Quest Diagnostics from 2003 to 2010. From 1991 to 2003, Dr. Albitar held various faculty positions at the University of Texas MD Anderson Cancer Center, including Chief of Leukemia Section in Laboratory Medicine and Pathology Department, Director of the molecular laboratory and Director of Hematopathology Fellowship program. Dr. Albitar was a tenured full professor in Pathology and Leukemia at the time of leaving MD Anderson Cancer Center. Dr. Albitar residency in AP/CP pathologist was at Brown University in Providence, Rhode Island and fellowship training in Hematopathology at the University of Pennsylvania. After his training in Hematopthology, Dr. Albitar spend 4 years in NIH sponsored Physician/Scientist training program at the University of Pennsylvania/Howard Hughes Medical Institute and the Department of Genetics. Dr. Albitar has published more than 300 peer-reviewed papers, book chapters, and review articles. He is the lead inventor on more than 60 different patents and patent applications. He is very well recognized leader in molecular and genomic diagnosis research and development”
Dean, College of Public Health; Professor, Epidemiology, University of Kentucky
Donna K. Arnett is Dean of the College of Public Health and Professor of Epidemiology at the University of Kentucky. Prior to this, Dr. Arnett was associate dean and chair of the Epidemiology Department at the University of Alabama-Birmingham. Dr. Arnett has received continuous NIH research funding for more than 20 years. Her work has focused primarily on the genomics and epigenomics of cardiovascular disease and related phenotypes. She has served as principal investigator for studies investigating the inherited basis of left ventricular hypertrophy and dyslipidemias as well as pharmacogenomic studies of response to antihypertensives and a lipid-lowering drug. Dr. Arnett has published numerous book chapters, edited volumes, and over 600 peer-reviewed papers in such journals as JAMA, Nature, and the full range of cardiovascular and genomic science publications.
Brad Bostic has been founding, leading, and investing in high-growth technology companies for the past 25 years. Frustrated by the prevalence of one-size-fits-all, trial and error patient care, Brad founded hc1 to save lives, save money, and eliminate wasteful practices with precision health insights that empower patients, providers, and health plans to make tailored care decisions. Today, the hc1 Platform analyzes billions of live data points across 20, 000 provider locations to personalize care, improve outcomes, and eliminate waste for tens of millions of patients each year. By transforming lab and prescription data into personalized healthcare insights with cloud computing and machine learning, hc1 is the leader in critical insights, analytics, and solutions for precision health. Brad is among the top innovators in healthcare according to Becker’s Healthcare and was recognized as the 2020 Dynamic Leader of the Year by the Indiana Chamber of Commerce.
Dean, Robert A Knox Professor, School of Public Health, Boston University
Sandro Galea, a physician, epidemiologist, and author, is dean and Robert A. Knox Professor at Boston University School of Public Health. He previously held academic and leadership positions at Columbia University, the University of Michigan, and the New York Academy of Medicine. He has published extensively in the peer-reviewed literature, and is a regular contributor to a range of public media, about the social causes of health, mental health, and the consequences of trauma. He has been listed as one of the most widely cited scholars in the social sciences. He is chair of the board of the Association of Schools and Programs of Public Health and past president of the Society for Epidemiologic Research and of the Interdisciplinary Association for Population Health Science. He is an elected member of the National Academy of Medicine. Galea has received several lifetime achievement awards. Galea holds a medical degree from the University of Toronto, graduate degrees from Harvard University and Columbia University, and an honorary doctorate from the University of Glasgow.
David Gambino, MS
Vice President, Transformation & Pharmacy, Horizon Blue Cross Blue Shield of New Jersey
David Gambino is Vice President, Transformation & Pharmacy, at Horizon BCBSNJ, the state’s largest health insurer, covering nearly 3.7 million members. In this role, Mr. Gambino has overall accountability for health care transformation, value based provider contracts, health care technology enablement, and social determinants of health strategy. Mr. Gambino also oversees pharmacy strategy and operations for Horizon BCBSNJ’s Commercial, Medicare and Medicaid pharmacy areas.
Prior to joining Horizon BCBSNJ in 2016, Mr. Gambino was the Chief Strategy Officer at Ascension Via Christi, a Kansas-based integrated hospital system. In this role, he led the development of strategies to increase revenue and market share through strategic partnerships, expanded system capabilities and increased value to members. These strategies included the development of a clinically integrated network capable of managing risk that approached 100,000 lives in valued-based arrangements under his leadership.
Prior to Ascension Via Christi, Mr. Gambino was Vice President of Business Development and Marketing at CHI Health, a Nebraska-based integrated hospital system, where he led business innovation and strategy management. Prior to his tenure at CHI Health, he held both clinical and non-clinical senior level positions in several hospital systems.
Mr. Gambino earned a Bachelor of Science degree in Pharmacy, from Wayne State University in Michigan, and a Master of Science Administration degree in Health Services Administration from Central Michigan University. for outstanding cancer research.
Kevin Hrusovsky is a 30-year biotechnology veteran with a proven track record of commercializing disruptive technologies, and an industry visionary passionate about revolutionizing healthcare from a broken system focused on “treating the sick” to an empowered industry able to prevent diseases before symptoms occur. He holds an M.B.A. from Ohio University and a B.S. in Mechanical Engineering from The Ohio State University. He received an Honorary Doctorate from Framingham State University and helped build competitive strategy curriculum at the Institute for Strategy & Competitiveness at Harvard Business School. Hrusovsky currently serves as the President, Chairman and CEO of Quanterix, a company digitizing biomarker analysis to advance precision health, and is the founder of Powering Precision Health (PPH), a non-profit global think tank composed of the industry’s top medical, research and finical experts. Through his non-profit network and the power of Quanterix’ disruptive Simoa technology, Hrusovsky is accelerating critical advances across neurology, oncology, infectious disease, cardiology and inflammation. Most recently, he spearheaded a newly formed Emergency COVID-19 Diagnostic & Drug PPH Advisory Panel that aims to enhance global understanding of COVID-19 and innate and adaptive immuno response to drive earlier intervention in the disease cascade, deliver more targeted therapeutic responses, and accelerate development of emerging drugs and vaccines. Today, the company’s high-definition biomarker platform and ultra-sensitive assays are validated by more than 780 peer-reviewed studies and are being used to support critical research in healthcare, academia and pharmaceutical institutions across the globe.
Co-founder and Chief Executive Officer, 908 Devices Inc.
Dr. Kevin Knopp is a Co-founder & CEO of 908 Devices Inc. An experienced high-tech entrepreneur, Kevin co-founded Ahura Scientific in 2002, and was Senior Vice President overseeing Operations, R&D and Safety and Security Sales through Ahura’s acquisition by Thermo Fisher Scientific in 2010, where he continued as Vice-President and Site Leader of the Portable Optical Analysis division. Kevin served as an independent board member for Crystal IS until its acquisition by Asahi-Kasei. He earned B.S.E.E from Boston University, M.S.E.E, and Ph.D. degrees in Optics from the University of Colorado. Kevin is an inventor on more than 20 US patents, is an author on more than a dozen refereed publications, and his products have received R&D 100, Business Week IDEA, GSN, CPhI Gold, Cygnus, and Frost & Sullivan awards.
Chief Medical Informatics Officer, Medix Technology
With over 20 years’ experience in healthcare informatics, Dr. Patty is currently CMIO at Medix Technology where he is part of the Consulting and Advisory team providing services across the full duration of an organization’s Epic journey including implementation planning, implementation project directorship, post-live performance improvement, physician satisfaction and efficiency improvement and Epic optimization.
Executive Chairman and Chief Executive Officer, Outcomes Matter Innovations, LLC
Andrew L. Pecora, MD, FACP, CPE, is the Executive Chairman and CEO of Outcomes Matter Innovations, LLC (OMI), a Jersey City based company focused on technology enablement that facilitates a new business model in Value-Based Care Reimbursement for Specialty physicians, as well as management services for established healthcare providers throughout the Northeast.
Dr. Pecora comes to OMI from Hackensack Meridian Health, where he was President, Physician Enterprise and Chief Innovation Officer. While there, he helped create and led development of the John Theurer Cancer Center and played a key role in the success of many of Hackensack Meridian strategic partnerships, including those with Memorial Sloan Kettering Cancer Center and Georgetown Lombardi Cancer Center. He has also been a champion in engaging physician leaders to innovate and transform health care delivery since 1990.
Dr. Pecora is one of the world’s experts in blood and marrow stem-cell transplantation, cellular medicine, and immunology research. He has led award-winning research funded by the National Cancer Institute and the AHEPA Research Foundation and has been involved in clinical evaluation of novel agents including cancer vaccines, replication competent viruses and targeted therapies. He has also been involved in laboratory and clinical development of engineered blood and marrow stem-cell grafts for autologous and allogeneic transplantation, as well as cell therapy for regenerative medicine.
Dr. Pecora’s award-winning research has been published in many prestigious medical journals and has been funded by organizations including the National Cancer Institute, Amgen, Merck and the AHEPA Research Foundation. He is a Professor of Medicine at University of Medicine and Dentistry of New Jersey (NJMS) – New Jersey Medical School, at which he earned his medical degree as well as a Professor of Medicine and Oncology at Georgetown University. He completed his residency at The New York Hospital in internal medicine and conducted his fellowship training at Memorial Sloan-Kettering Cancer Center in hematology/oncology.
Dr. Pecora’s awards and honors include America’s Top Doctors, Who’s Who in the World, the ASCO Cancer Foundation Research Award and the Gallo Award for outstanding cancer research.